Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Income from Continuing Operations (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Income from Continuing Operations readings, the most recent being 22592000.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations rose 164.57% to 22592000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 73058000.0, a 887.6% increase, with the full-year FY2025 number at 59005000.0, up 266.12% from a year prior.
  • Income from Continuing Operations hit 22592000.0 in Q1 2026 for Kiniksa Pharmaceuticals International, up from 14199000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 224093000.0 in Q3 2022 to a low of 90632000.0 in Q4 2022.
  • Median Income from Continuing Operations over the past 5 years was 3908000.0 (2024), compared with a mean of 2362529.41.
  • Biggest five-year swings in Income from Continuing Operations: crashed 126.1% in 2024 and later surged 1269.6% in 2025.
  • Kiniksa Pharmaceuticals International's Income from Continuing Operations stood at 90632000.0 in 2022, then increased by 8.39% to 83032000.0 in 2023, then skyrocketed by 98.54% to 1214000.0 in 2024, then surged by 1269.6% to 14199000.0 in 2025, then skyrocketed by 59.11% to 22592000.0 in 2026.
  • The last three reported values for Income from Continuing Operations were 22592000.0 (Q1 2026), 14199000.0 (Q4 2025), and 18435000.0 (Q3 2025) per Business Quant data.